Viz.ai

Viz.ai announced today that the FDA granted de novo approval to its Viz HCM module for detecting hypertrophic cardiomyopathy.

San Francisco-based Viz.ai says this creates a new regulatory category for cardiovascular machine learning-based notification software. The company supports its algorithm’s deployment through a multi-year agreement with Bristol Myers Squibb. They struck that partnership deal in March of this year.

With Viz HCM — integrated into the Viz.ai platform — providers can identify more patients with suspected HCM earlier using AI. They can then receive triage and diagnosis for further evaluation.

The Viz HCM module automatically reviews routine electrocardiograms (ECGs) from across a health system. It identifies suspected HCM cases and notifies the appropriate cardiologists and care team on the Viz mobile application. Clinicians can then easily review the patient’s ECG and coordinate follow-up for diagnosis. They can then use t…

Those conditions include pulmonary embolism, right heart strain, aortic dissection and abdominal aortic aneurysm (AAA).

San Francisco-based Viz.ai submitted a 510(k) application to the FDA for the AI-powered software, according to a news release.

Viz.ai CEO Chris Mansi said the platform helps clinical teams “achieve better clinical outcomes.” He touted positive feedback from early adopters and said the company plans to expand access to the suite. Viz.ai currently has a hospital customer base totaling more than 1,300.

“We set out to build a solution where any patient with life-threatening diseases can benefit from AI-powered care coordination with triage and real-time mobile communication,” said Mansi.

The Viz Vascular Suite uses AI to automa…

Viz.ai announced today that it launched an AI-powered radiology suite for alerting radiologists and connecting care teams in real-time.

San Francisco-based Viz.ai designed the suite to alert radiologists in their workflow of suspected diseases. It also prioritizes worklists and connects care teams while integrating into picture archiving and communications systems (PACS). This helps to securely facilitate access to imaging data across departments while streamlining patient diagnosis.

“With an increasing demand for imaging studies and a global shortage of radiologists, technologies that can be easily integrated into radiology workflows to enhance efficiency and streamline patient care are sorely needed,” said Dr. Allan Brook, director of interventional neuroradiology at Montefiore Medical Center and professor of radiology and neurosurgery at Albert Einstein College of Medicine. “The Viz Radiology Suite offers radiologists important capabilities for optimizing im…

Viz.ai announced today that it received FDA 510(k) clearance for its Viz Subdural (SDH) artificial intelligence (AI) algorithm.

San Francisco-based Viz.ai designed its Viz SDH algorithm to use AI to automatically detect subdural hemorrhage, enabling physicians to triage patients effectively and deliver optimal care.

The company said in a news release that its Viz SDH represents the only SDH-specific, AI-powered detection and care coordination platform with the ability to identify acute and chronic subdural bleeds, then quickly notify the care team to mobilize in case an immediate intervention is necessary.

“Viz SDH allows us to detect both acute and chronic subdural hemorrhages to better identify early treatment pathways. Acute subdurals require urgent intervention. Therefore, prompt notification will allow us to improve outcomes in emergent cases. Chronic subdurals have a very different pathway and having an algorithm that identifies both can allow us t…

Artificial intelligence-based disease detection technology company Viz.ai announced today that it raised $100 million in a Series D financing round.

San Francisco-based Viz.ai develops AI algorithms that detect disease and offer hospital systems a way to ensure that, once detected, the patients are captured and workflows across an entire health system are standardized. The latest algorithm for detecting suspected cerebral aneurysms received FDA clearance in February.

According to a news release, the financing round comes on the back of the company reaching the milestone of more than 1,000 hospitals using the Viz Platform.

Tiger Global and Insight Partners led the financing round, while a number of early backers, including Scale Ventures, Kleiner Perkins, Threshold, GV (formerly Google Ventures), Sozo Ventures, CRV and Susa participated.

Viz.ai said in the release that the new funds will be used to support its growth trajectory as it seeks to expan…

San Francisco-based Viz.ai said in a news release that the new modules allow for faster clinical decision making and improved care coordination for patients with the two life-threatening conditions. The company is debuting the modules at the 48th annual VEITHsymposium November 16 – 20 in Orlando, Florida.

The modules use deep learning to identify suspected aortic dissection and pulmonary embolism disease in under two minutes. Viz.ai designed them to ensure that the correct clinical decisions are made at the right time regardless of where a patient resides in the healthcare system.

Users can access all aortic and pulmonary imaging from the cloud, while the modules use their advanced deep learning capabilities to communicate time-sensitive information, including advanced imaging studies and real-time clinical…